175 filings
8-K
AMLN
Amylin Pharmaceuticals Inc
13 Aug 12
Entry into a Material Definitive Agreement
12:00am
8-K
AMLN
Amylin Pharmaceuticals Inc
3 Jul 12
Entry into a Material Definitive Agreement
12:00am
8-K
AMLN
Amylin Pharmaceuticals Inc
2 Jul 12
Other Events
12:00am
8-K
AMLN
Amylin Pharmaceuticals Inc
18 Jun 12
Other Events
12:00am
8-K
AMLN
Amylin Pharmaceuticals Inc
5 Jun 12
Other Events
12:00am
8-K
o0whu9
16 May 12
Departure of Directors or Certain Officers
12:00am
8-K
mbb293t lotcu4jgvg
15 May 12
Departure of Directors or Certain Officers
12:00am
8-K
lfxpu1i x1be0trtvpg
26 Apr 12
Amylin Pharmaceuticals Reports First Quarter 2012 Financial Results
12:00am
8-K
of8hrbc6rmjh8v
9 Mar 12
Amylin Pharmaceuticals Announces Public Offering of Common Stock
12:00am
8-K
g55cc
6 Mar 12
Departure of Directors or Certain Officers
12:00am
8-K
pt6xeywhwqdfteai
9 Feb 12
Entry into a Material Definitive Agreement
12:00am
8-K
qv8cvcuzuf xvi6q5v
6 Feb 12
Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
12:00am
8-K
6x50cl
30 Jan 12
FDA Approves BYDUREON™ – The First and Only Once-Weekly Treatment
12:00am
8-K
ez8e5gw9 cx8d
7 Dec 11
Departure of Directors or Certain Officers
12:00am
8-K
n9ot8fu oe
8 Nov 11
Entry into a Material Definitive Agreement
12:00am
8-K
p476xtj6
20 Oct 11
Patients in Pivotal Study Achieved Better Glycemic Control Without Weight Gain or Increased Hypoglycemia Risk Versus Insulin Glargine
12:00am
8-K
1hyylf3mx3oy1cn
19 Oct 11
Amylin Pharmaceuticals Reports Third Quarter Financial Results
12:00am
8-K
elcb jkv1
28 Jul 11
Other Events
12:00am
8-K
4rfse uu5
26 Jul 11
Amylin Pharmaceuticals Reports Second Quarter Financial Results
12:00am
8-K
e7qrjff02iugl1wwihk
8 Jul 11
Results to be Included in BYDUREON™ New Drug Application Resubmission in the Third Quarter of 2011
12:00am